The longevity peptide category has expanded dramatically as researchers identify endogenous peptides that decline with age and appear to drive aspects of the aging phenotype. Unlike anti-aging cosmetic claims, the best-studied longevity peptides — Epithalon, GHK-Cu, Humanin, MOTS-c, and SS-31 — work through specific, mechanistically grounded pathways: telomere biology, mitochondrial function, cellular senescence, and tissue repair signalling. This guide covers the strongest candidates and what a research-based longevity protocol might include.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Most longevity peptides show the greatest effect in models of age-related decline — meaning their target mechanisms are most relevant in middle age and beyond (typically 40+). That said, GHK-Cu's tissue repair benefits are relevant at any age, and GH secretagogues are commonly used across age groups. There is no established minimum age for research use of these compounds.
Epithalon: Telomere-Directed Anti-Aging
Epithalon (Epitalon) is a tetrapeptide developed by the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson, who has published extensively on bioregulator peptides over 40+ years. Its primary studied mechanism is activation of telomerase — the enzyme that extends telomeres, the protective caps on chromosomal DNA that shorten with each cell division. Shortened telomeres are associated with cellular senescence, reduced tissue regeneration, and aspects of the aging phenotype.
In animal studies, Epithalon extended mean and maximum lifespan in mice, reduced age-related tumour incidence, restored circadian rhythm disruption, and improved pineal gland function (melatonin production). Human data comes primarily from small Russian clinical studies showing improved sleep quality, immune function, and melatonin levels in elderly subjects. A rigorous Western clinical trial program does not yet exist. The most common research protocol involves 5–10 mg daily for 10–20 days, run 1–2 times per year — mirroring the cycles used in Russian clinical studies.
GHK-Cu: Tissue Repair and Gene Expression
GHK-Cu (copper peptide GHK) is a naturally occurring tripeptide that declines with age — serum GHK-Cu concentrations fall from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. This decline correlates with reduced tissue repair capacity and changes in gene expression patterns that mirror aging. GHK-Cu activates over 4,000 genes according to genomic analysis, predominantly in tissue repair, anti-inflammatory, and antioxidant directions — with simultaneous downregulation of genes associated with cancer aggression and inflammatory disease.
Its longevity relevance extends beyond skin repair: systemic GHK-Cu administration in animal models has shown lung tissue restoration, neurological protection, anti-tumour effects, and normalisation of gene expression patterns toward younger profiles. For longevity protocols, systemic subcutaneous GHK-Cu (1–2 mg/day) alongside topical application represents a rational research approach targeting multiple aspects of the aging phenotype.
Mitochondrial Peptides: Humanin, MOTS-c, SS-31
Mitochondrial dysfunction is now considered a primary driver of aging, and a class of peptides encoded within mitochondrial DNA — called mitochondria-derived peptides (MDPs) — appears to oppose this decline. Humanin and MOTS-c are the best-studied MDPs. Both decline with age, and both show protective effects in age-related disease models spanning cardiovascular disease, neurodegenerative disease, metabolic dysfunction, and cancer.
SS-31 (Elamipretide) is a synthetic mitochondria-targeting peptide that concentrates in the inner mitochondrial membrane and reduces oxidative damage to cardiolipin — a phospholipid critical for mitochondrial cristae structure and ATP production. SS-31 has reached Phase II/III clinical trials for heart failure and Barth syndrome. In animal longevity studies, SS-31 improved mitochondrial function, reduced ROS production, and reversed age-related declines in physical capacity in old mice.
For longevity protocols, this mitochondrial triad — Humanin, MOTS-c, SS-31 — targets the bioenergetic decline that appears fundamental to the aging process. Humanin is typically dosed at 1–5 mg 3×/week, MOTS-c at 5–10 mg 3×/week, and SS-31 at 1–3 mg/day subcutaneously.
Constructing a Longevity Protocol
A rational longevity research protocol typically layers compounds across complementary mechanisms rather than relying on a single peptide. A common structure among longevity researchers: run Epithalon cycles 1–2 times per year (telomere/circadian/pineal axis), maintain GHK-Cu systemically or topically year-round (tissue repair, gene expression), and cycle mitochondrial peptides (Humanin, MOTS-c, or SS-31) during the off-Epithalon periods.
Growth hormone secretagogues (CJC-1295/Ipamorelin or MK-677) are often included in longevity protocols given GH's decline with age and its role in tissue maintenance. IGF-1 LR3 adds anabolic support for preserving lean mass, which declines with aging. The full longevity stack can become complex — most practitioners start with one compound, establish baseline and response, then add sequentially.
Longevity Peptide Protocol Reference
| Peptide | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Epithalon | 5–10 mg/day | SubQ or IV | 10–20 day cycle, 1–2×/year | Telomerase, pineal, circadian |
| GHK-Cu | 1–2 mg/day | SubQ or topical | Year-round or 8–12 week cycles | Gene expression, tissue repair |
| Humanin | 1–5 mg | SubQ | 3×/week | Mitochondrial / metabolic protection |
| MOTS-c | 5–10 mg | SubQ | 3×/week | Mitochondrial / AMPK activation |
| SS-31 | 1–3 mg/day | SubQ | Daily cycles | Mitochondrial membrane integrity |
| CJC-1295/Ipamorelin | 100/100 mcg | SubQ | 5×/week, pre-sleep | GH pulse preservation |
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Epithalon has the largest body of dedicated longevity research, with 40+ years of Russian scientific study including animal lifespan extension and human clinical data. GHK-Cu has the most genomic evidence — over 4,000 gene expression changes have been documented. SS-31 has the strongest Western clinical trial program (Phase II/III). Each leads in a different evidence domain.
NAD+ precursors (NMN, NR) restore cellular NAD+ levels, which decline with age and are critical for sirtuins and mitochondrial function. Longevity peptides work through different mechanisms — telomerase activation, direct mitochondrial protection, tissue repair signalling. Many longevity researchers combine both approaches: NAD+ precursors for intracellular energy metabolism and longevity peptides for structural and signalling interventions. They are complementary rather than alternatives.
Epithalon has a 40+ year clinical use history in Russia with no reported serious adverse effects in published studies. The short cyclical dosing schedule (10–20 days, 1–2 times per year) minimises chronic exposure risks. However, no large-scale, long-term Western safety trials exist. Standard precautions apply: individuals with active cancer, autoimmune conditions, or on immunosuppressants should consult a physician before use.
Most longevity peptides show the greatest effect in models of age-related decline — meaning their target mechanisms are most relevant in middle age and beyond (typically 40+). That said, GHK-Cu's tissue repair benefits are relevant at any age, and GH secretagogues are commonly used across age groups. There is no established minimum age for research use of these compounds.
Yes — the longevity peptide stack approach is based on layering compounds across different mechanisms to cover more hallmarks of aging simultaneously. There are no known antagonistic interactions between the compounds discussed here. Practical considerations (cost, injection frequency, monitoring) usually limit how many are used concurrently rather than biological concerns about combination.